Health Care Equity and BRCA1/2 Testing
Although most cancers are sporadic, a significant proportion are related to inherited cancer-causing genes called pathogenic germline variants (PGVs). There are recommended measures for prevention and earlier diagnosis of cancers in patients identified as BRCA1 and BRCA2 PGV carriers, which are the...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mary Ann Liebert
2025-02-01
|
| Series: | Health Equity |
| Subjects: | |
| Online Access: | https://www.liebertpub.com/doi/10.1089/heq.2024.0167 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850277333072609280 |
|---|---|
| author | Steven Sorscher |
| author_facet | Steven Sorscher |
| author_sort | Steven Sorscher |
| collection | DOAJ |
| description | Although most cancers are sporadic, a significant proportion are related to inherited cancer-causing genes called pathogenic germline variants (PGVs). There are recommended measures for prevention and earlier diagnosis of cancers in patients identified as BRCA1 and BRCA2 PGV carriers, which are the most common cancer-predisposing PGVs. For example, published guidelines recommend that patients with BRCA1/2 PGVs undergo bilateral oophorectomies to prevent ovarian cancer and regular magnetic resonance imaging to screen for breast cancer. Also, those same measures are recommended for family members identified by cascade testing as BRCA1/2 carriers. Here, reports of the significant disparities between groups in which patients diagnosed with breast cancer are offered and undergo testing for BRCA1/2 PGVs are reviewed. Expanding the current standard of care guidelines for BRCA1/2 testing to all patients diagnosed with breast cancer and enacting the Cancer Moonshot 2.0 Initiative measures that should mitigate these disparities are discussed as well. |
| format | Article |
| id | doaj-art-43f6c46abb90486abab7439d95e9b54e |
| institution | OA Journals |
| issn | 2473-1242 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Mary Ann Liebert |
| record_format | Article |
| series | Health Equity |
| spelling | doaj-art-43f6c46abb90486abab7439d95e9b54e2025-08-20T01:49:55ZengMary Ann LiebertHealth Equity2473-12422025-02-019112713010.1089/heq.2024.0167Health Care Equity and BRCA1/2 TestingSteven Sorscher0Winston-Salem, North Carolina, USA.Although most cancers are sporadic, a significant proportion are related to inherited cancer-causing genes called pathogenic germline variants (PGVs). There are recommended measures for prevention and earlier diagnosis of cancers in patients identified as BRCA1 and BRCA2 PGV carriers, which are the most common cancer-predisposing PGVs. For example, published guidelines recommend that patients with BRCA1/2 PGVs undergo bilateral oophorectomies to prevent ovarian cancer and regular magnetic resonance imaging to screen for breast cancer. Also, those same measures are recommended for family members identified by cascade testing as BRCA1/2 carriers. Here, reports of the significant disparities between groups in which patients diagnosed with breast cancer are offered and undergo testing for BRCA1/2 PGVs are reviewed. Expanding the current standard of care guidelines for BRCA1/2 testing to all patients diagnosed with breast cancer and enacting the Cancer Moonshot 2.0 Initiative measures that should mitigate these disparities are discussed as well.https://www.liebertpub.com/doi/10.1089/heq.2024.0167oncologyBRCA1/2 testinghealth equity |
| spellingShingle | Steven Sorscher Health Care Equity and BRCA1/2 Testing Health Equity oncology BRCA1/2 testing health equity |
| title | Health Care Equity and BRCA1/2 Testing |
| title_full | Health Care Equity and BRCA1/2 Testing |
| title_fullStr | Health Care Equity and BRCA1/2 Testing |
| title_full_unstemmed | Health Care Equity and BRCA1/2 Testing |
| title_short | Health Care Equity and BRCA1/2 Testing |
| title_sort | health care equity and brca1 2 testing |
| topic | oncology BRCA1/2 testing health equity |
| url | https://www.liebertpub.com/doi/10.1089/heq.2024.0167 |
| work_keys_str_mv | AT stevensorscher healthcareequityandbrca12testing |